Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Localized Chemotherapy to the Liver Spares Healthy Tissue

18.08.2004


In this retrospective study, eighty-eight patients with advanced hepatocellular carcinoma (HCC) were treated with long-term chemotherapy infusion into the hepatic artery, the main artery that supplies the liver. Known as hepatic arterial chemotherapy, this treatment requires a reservoir/pump system to supply the drug directly to the liver and the liver cancer. The reservoir port systems currently available have to be surgically implanted, making this treatment unavailable to many patients who were unable or unwilling to have the implant. Interventional radiologists -- vascular experts who are uniquely skilled in using the vascular system to deliver targeted treatments via catheter throughout the body -- adapted conventional venous ports to use in the arterial circulation. In this method, the interventional radiologist implanted the reservoir and then embolized – mechanically blocked – the arteries to the adjacent areas during the port placement to prevent the influx of drugs to areas outside of the liver. This is beneficial because the chemotherapy drug is only circulated to the organ with the cancer, so the drug does not harm healthy tissue throughout the body. This allows for a higher dose of chemotherapy drug to be used, because the drug is contained.

Hepatic Arterial Infusion Chemotherapy

The hepatic arterial infusion chemotherapy was initiated after reservoir implantation on an outpatient basis. The infusion protocols were decided for each patient by the physician in charge and chemotherapeutic agents were administered every 1–4 weeks. In 55 patients, cisplatin (10 mg/m2) and 5-fluorouracil (1,000 mg/m2) were given at 1 hour and 5 hours, respectively. In the other 33 patients, doxorubicin hydrochloride or epirubicin hydrochloride (10–20 mg/m2) were injected every 2–4 weeks in a "one-shot" manner.



Implantation of Reservoir and Response to Arterial Infusion Chemotherapy
Reservoirs were successfully implanted in all patients. Arterial infusion chemotherapy was performed 13.1 times per patient on average. Tumors completely disappeared in one patient (complete response, 1%), shrunk at least 50% in maximum diameter in 14 patients (partial response, 16%), shrunk 25%–50% in five patients (minor response, 6%), and remained stable in 68 patients (77%). No tumors showed progression. The tumor response rate (complete and partial responses) was 17%.

Survival

The follow-up period ranged from 1.4 months to 41.4 months, with a mean of 12.0 months. The estimated 1-, 2-, and 3-year survival rates were 55%, 36%, and 24% in all patients, with a mean survival period of 19.5 months ± 1.9.

This study showed similar results as those achieved in previous studies. The therapeutic response rate, 1-year survival rate, and mean survival time were 17%, 55%, and 19.5 months, respectively. By comparison, Okuda et al, analyzed the natural history of HCC and reported the prognoses of untreated patients. The median survival times were 0.7 months in patients with Okuda stage III disease, 2.0 months in those with stage II disease, and 8.3 months in those with stage I disease. The survival of patients with portal venous invasion has been reported to be 3–4 months. Arterial infusion chemotherapy seems to improve survival in patients with HCC. In the present study, the mean survival periods were more than 1 year even in patients with Okuda stage II/III disease (15 months) and in those with portal venous invasion (16 months).

Prognostic Factors Identified

In the univariable analysis, the following eight variables were significantly linked with better prognosis: (i) tumor extension less than 50% of liver volume, (ii) CLIP score 0–2, (iii) Okuda stage I, (iv) alkaline phosphatase level of less than 140 IU/L, (v) absence of ascites, (vi) aspartate aminotransferase level less than 80 IU/L, (vii) good therapeutic response, and (viii) lack of portal venous invasion. When multiple variables were analyzed, the CLIP score, Okuda stage, and therapeutic effect were found to be significant prognostic factors with independent value for survival.

Although these results should be confirmed in future prospective studies, these prognostic factors should prove helpful in determining which patients with advanced HCC may benefit from arterial infusion chemotherapy with an implanted port system.

| newswise
Further information:
http://www.sirweb.org
http://www.jvir.org

More articles from Health and Medicine:

nachricht Study tracks inner workings of the brain with new biosensor
16.08.2018 | Rheinische Friedrich-Wilhelms-Universität Bonn

nachricht Foods of the future
15.08.2018 | Georg-August-Universität Göttingen

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Unraveling the nature of 'whistlers' from space in the lab

A new study sheds light on how ultralow frequency radio waves and plasmas interact

Scientists at the University of California, Los Angeles present new research on a curious cosmic phenomenon known as "whistlers" -- very low frequency packets...

Im Focus: New interactive machine learning tool makes car designs more aerodynamic

Scientists develop first tool to use machine learning methods to compute flow around interactively designable 3D objects. Tool will be presented at this year’s prestigious SIGGRAPH conference.

When engineers or designers want to test the aerodynamic properties of the newly designed shape of a car, airplane, or other object, they would normally model...

Im Focus: Robots as 'pump attendants': TU Graz develops robot-controlled rapid charging system for e-vehicles

Researchers from TU Graz and their industry partners have unveiled a world first: the prototype of a robot-controlled, high-speed combined charging system (CCS) for electric vehicles that enables series charging of cars in various parking positions.

Global demand for electric vehicles is forecast to rise sharply: by 2025, the number of new vehicle registrations is expected to reach 25 million per year....

Im Focus: The “TRiC” to folding actin

Proteins must be folded correctly to fulfill their molecular functions in cells. Molecular assistants called chaperones help proteins exploit their inbuilt folding potential and reach the correct three-dimensional structure. Researchers at the Max Planck Institute of Biochemistry (MPIB) have demonstrated that actin, the most abundant protein in higher developed cells, does not have the inbuilt potential to fold and instead requires special assistance to fold into its active state. The chaperone TRiC uses a previously undescribed mechanism to perform actin folding. The study was recently published in the journal Cell.

Actin is the most abundant protein in highly developed cells and has diverse functions in processes like cell stabilization, cell division and muscle...

Im Focus: Lining up surprising behaviors of superconductor with one of the world's strongest magnets

Scientists have discovered that the electrical resistance of a copper-oxide compound depends on the magnetic field in a very unusual way -- a finding that could help direct the search for materials that can perfectly conduct electricity at room temperatur

What happens when really powerful magnets--capable of producing magnetic fields nearly two million times stronger than Earth's--are applied to materials that...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Within reach of the Universe

08.08.2018 | Event News

A journey through the history of microscopy – new exhibition opens at the MDC

27.07.2018 | Event News

2018 Work Research Conference

25.07.2018 | Event News

 
Latest News

Staying in Shape

16.08.2018 | Life Sciences

Diving robots find Antarctic seas exhale surprising amounts of carbon dioxide in winter

16.08.2018 | Earth Sciences

Protein droplets keep neurons at the ready and immune system in balance

16.08.2018 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>